Verve Therapeutics (VERV) Stock Price
Verve Therapeutics Price
Revenue has compounded at 308.1% per year over the past 2 years to 32.33 M USD. Verve Therapeutics's net margin stands at -614.6%, up from -8,108.6% several years earlier. Analysts set a median price target of 13.52 USD, implying 21.4% above the current price. Of 14 analysts, 6 rate the stock a buy — an overall Hold consensus.
Verve Therapeutics stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Verve Therapeutics business model & stock analysis
Frequently asked questions about Verve Therapeutics
Analysts currently set an average price target of 13.26 USD for the Verve Therapeutics stock (median: 13.52 USD), implying +19.1 % versus the latest price. The consensus is based on 14 analyst ratings.
14 analysts currently rate the Verve Therapeutics stock: 6 recommend buying, 8 holding and 0 selling. For 2026, analysts expect Verve Therapeutics to generate revenue of 16.08 M USD and earnings per share of -3.19 USD.
Converted at the current exchange rate, the Verve Therapeutics share trades at 9.97 EUR (11.13 USD).
The Verve Therapeutics share (VERV) is listed on 1 stock exchanges, including: NASDAQ (VERV).
The expected revenue of Verve Therapeutics is 16.08 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Verve Therapeutics is -277.14 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Verve Therapeutics is currently -3.49. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Verve Therapeutics stock.
The price-to-sales ratio (P/S) of Verve Therapeutics is currently 60.13. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Verve Therapeutics stock.
The Eulerpool Quality Score for Verve Therapeutics is 4/10.
The ISIN of Verve Therapeutics is US92539P1012. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Verve Therapeutics is VERV. The ticker symbol is used to trade Verve Therapeutics shares on the stock exchange.
Verve Therapeutics stock
Verve Therapeutics Peer Group
Verve Therapeutics Ticker
Verve Therapeutics FIGI
All fundamentals and in-depth analysis of Verve Therapeutics
Our stock analysis for Verve Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Verve Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.